accelerated vaccination ebola virus haemorrhagic fever non-human primates
containment highly lethal ebola virus outbreaks poses serious public health challenge although experimental vaccine successfully protected non-human primates disease six months required complete immunizations making impractical limit acute epidemic report development accelerated vaccination ebola virus non-human primates antibody response immunization adenoviral adv vector encoding ebola glycoprotein gp induced rapidly dna priming adv boosting lower magnitude determine whether earlier immune response nonetheless protect disease cynomolgus macaques challenged ebola virus vaccination adv-gp nucleoprotein np vectors protection highly effective correlated generation ebola-specific cd8+ t-cell antibody responses even animals immunized adv-gp/np challenged days later remained resistant challenge either low high doses virus accelerated vaccine provides intervention may help limit epidemic spread ebola applicable viruses
